USMCA — Lanton Law Blog

Tech Companies and the Uncertain Future of §230

While there has long been controversy surrounding how far regulating the Internet should go, it seemed that the 2016 election has had major impacts on how and what information consumers should and should not see. From the spread of hate speech, to broadcasted violence to the confusion over what is “legitimate” news, one law is at the center of what the responsibilities are of an Internet Service Provider (ISP): 47 U.S. Code § 230.

What Will Happen to Biosimilars in the USMCA Agreement in 2020?

Back in August I started an analysis of how biosimilars will be impacted in the new United States-Mexico-Canada Agreement (USMCA). To refresh, in a follow up on a 2016 campaign promise to renegotiate the North American Free Trade Agreement (NAFTA), the Administration has been engaging Mexico and Canada in an effort to create and ratify the USMCA.

Congress, healthcare, home infusion, HealthIT, biologics, BiosimilarsRon LantonDecember 23, 2019trade, USMCA

How Will the United States–Mexico–Canada Agreement Affect Biosimilars?

For years we have witnessed the fierce debate over whether the North American Free Trade Agreement (NAFTA) is serving the best interests of the United States. In following up on a 2016 campaign promise to renegotiate NAFTA, the new NAFTA, called the United States–Mexico–Canada Agreement (USMCA), is currently being debated by Congress, and there are concerns as to whether the agreement will be ratified.